Wedbush Analyst Laura Chico dropped the company a price target on peripheral therapeutics (Eutx) to $ 35 from $ 40 and keeps a better performing score on the shares. Edgewise said the FDA considered Canyon's data to be inadequate to support accelerated filing for Severeen in Becker muscular dystrophy, but the company will explore additional routes to speed up the process, and will seek full approval with Grand Canyon, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for Sevasemen in DMD as the patient population for study, the company said.
First published on Tefin -The pretty source for real -time financial news that moves in the market. Try now >>
See today's best performing stocks on Tipranks >>
Read more on EWTX: